Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Purdue Withdraws Palladone At FDA's Request Due To Alcohol Interaction

This article was originally published in The Pink Sheet Daily

Executive Summary

The company is immediately pulling extended-release hydromorphone off the market because of the potential for rapid release of the active ingredient into the bloodstream when the product is taken with alcohol, FDA and Purdue announce. FDA and Purdue note they have not received reports of alcohol-related serious adverse events with the opioid.

You may also be interested in...



King Signs On To Develop Pain Therapeutics’ Abuse-Resistant Oxycodone

The companies intend to file an NDA for the abuse-resistant oxycodone product Remoxy in 2007; King will fund Phase III.

King Signs On To Develop Pain Therapeutics’ Abuse-Resistant Oxycodone

The companies intend to file an NDA for the abuse-resistant oxycodone product Remoxy in 2007; King will fund Phase III.

Biovail’s Tramadol ER Approved Without Additional Clinical Studies

The company expects the analgesic to launch early in 2006, but continues negotiations over a marketing partnership.

Related Content

Topics

UsernamePublicRestriction

Register

ID1131849

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel